Pacira Biosciences Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Pacira Biosciences Inc in the third quarter 2026?
Pacira Biosciences inc achieved a return on average equity (ROE) of 5.53 % in its third quarter 2026, this is above PCRX's average return on equity of -14.07%.
Pacira Biosciences Inc shareholder's equity over the 12 months ending in its third quarter 2026 are valued at $683 million

ROE has advanced compared to 2.13% in the second quarter 2026, due to net income growth.

Within the Major Pharmaceutical Preparations industry 57 other companies had a higher return on equity. While the total ranking for ROE unchanged, relative to the second quarter 2026 at no. 2240.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Equity Change	-2.05 %	-11.32 %	-18.11 %	-10.95 %	-
Y / Y Net Income Change	425.06 %	-	-39.4 %	-89.79 %	-
Net Income (TTM) in Millions	38	15	5	7	21
Return On Equity (TTM)	5.53 %	2.13 %	0.73 %	0.95 %	2.8 %
PCRX's Total Ranking	# 2240	# 2240	# 1284	# 1807	#
Equity (TTM) in Millions	712	672	654	693	727
Seq. Equity Change	6 %	2.77 %	-5.66 %	-4.69 %	-4.03 %
Seq. Net Income Change	512.96 %	59.57 %	78.13 %	-69.86 %	-

Back to PCRX Management Effectiveness >> PCRX's 5 Years Annual ROE >> Compare PCRX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 58
Sector	# 180
Overall	# 2240

Return On Equity Statistics
High	Average	Low
29.64 %	-14.07 %	-116.57 %
(Sep 30 2020)		(Dec 31 2013)

PCRX Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	693	778	870	775	730
Y / Y Equity Change	-10.95 %	-10.55 %	12.27 %	6.11 %	17.87 %
Net Income in Millions	7	-100	42	16	42
Y / Y Net Income Change	-	-	163.72 %	-62.1 %	-71.15 %
Return On Equity	1.01 %	-12.79 %	4.82 %	2.05 %	5.75 %

Back to PCRX Management Effectiveness >> PCRX's 5 Years Annual ROE >> Compare PCRX ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 1.01 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PCRX's' Return on Equity at Yahoo Finance
PCRX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PCRX's Competitors
Subscribers only: Roe for Pacira Biosciences Inc 's Suppliers
Subscribers only: Return On Equity for PCRX's Customers

Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector	ROE
Regeneron Pharmaceuticals Inc	15.07 %
Bio rad Laboratories Inc	14.07 %
Boston Scientific Corporation	13.75 %
Inspire Medical Systems inc	12.49 %
Haemonetics Corporation	12.07 %
Labcorp Holdings Inc	11.55 %
Henry Schein Inc	11.29 %
Medinotec Inc	10.97 %
Tactile Systems Technology Inc	10.73 %
Penumbra Inc	10.44 %
Teleflex Incorporated	9.67 %
Merit Medical Systems Inc	9.65 %
U S Physical Therapy Inc	9.48 %
Pacific Health Care Organization Inc	8.10 %
Incyte Corporation	7.08 %
Conmed Corporation	7.07 %
Teva Pharmaceutical Industries Limited	6.37 %
Integer Holdings Corporation	6.02 %
Avantor Inc	5.96 %
Ligand Pharmaceuticals Incorporated	5.22 %
Lifestance Health Group Inc	4.82 %
Jazz Pharmaceuticals Plc	4.62 %
Pfizer Inc	4.62 %
Innovage Holding Corp	4.52 %
Icu Medical Inc	2.81 %
Biogen Inc	1.86 %
Integra Lifesciences Holdings Corp	1.24 %

Date modified: 2026-11-07T13:19:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.